摘要
目的:探讨血管紧张素转化酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)类药物对晚期胃癌合并高血压患者预后的影响。方法:采用回顾性研究法,收集2009年1月1日-2012年12月31日在浙江省肿瘤医院接受过至少2个周期含氟类药物的一线化疗方案,且经组织学证实为Ⅲ~Ⅳ期胃癌合并高血压患者的临床资料进行汇总分析。将其中服用ACEI/ARB类降压药物的患者设为试验组,服用其他降压药物的患者设为对照组,并进行电话随访。结果:符合入组条件的患者共124例,其中试验组患者(23例)与对照组患者(101例)除饮酒史外,在年龄、性别、吸烟史、体力状况评分、疾病家族史、肿瘤家族史、TNM分期、病理类型、肿瘤部位和化疗方案方面,差异均无统计学意义(P>0.05)。试验组患者一线化疗的有效率为73.9%,明显高于对照组的41.6%,差异有统计学意义(P<0.05);两组患者的1年和3年生存率比较,差异无统计学意义(P>0.05);试验组患者的中位生存时间为669 d,明显长于对照组患者的410 d,差异有统计学意义(P<0.05)。COX回归分析结果表明,一线化疗疗效对于不同降压药物组患者的生存有影响(P<0.05)。结论:与其他降压药物相比,ACEI/ARB类药物使晚期胃癌合并高血压患者一线化疗的有效率显著提高,中位生存时间也显著延长,但对于生存率的影响并不明显;同时,尚缺乏对患者具体饮酒量的统计比较,有待于多中心、前瞻性、大样本的研究进一步证实。
OBJECTIVE： To explore the effects of angiotensin converting enzyme inhibitors （ACEI）/angiotensin 11 receptor blockers （ARB） on the prognosis in patients with advanced gastric cancer complicated with hypertension. METHODS： By retro- spective study, clinical information of histologically confirmed III-IV stage advanced gastric cancer patients with hypertension receiving 2 cycles of first-line chemotherapy plan containing fluorouracil at least were collected from Zhejiang Tumor Hospital during Jan. 1st, 2009-Dec. 31th, 2012. The data were summarized and analyzed. The patients receiving ACEI/ARB drugs were included in trial group, and the patients receiving other antihypertensive drugs were included in control group. Telephone follow-up was con- ducted in 2 groups. RESULTS ： A total of 124 patients meeting the inclusion criteria were enrolled in this study. There was no statis-tical significance in age, gender, smoking history, ECOG score, family history of disease, family history of tumor, TNM stag- ing, pathological type, tumor site or chemotherapy plan between trial group （23 cases） and control group （101 cases）, except for history of alcohol intake （P-0.05）. Total response rate of first-line chemotherapy was 73.9% in trial group, which was significant- ly higher than 41.6% of control group, with statistical significance （P〈0.05）. There was no statistical significance in 1-year or 3-year survival rate between 2 groups （P〉0.05）. Median survival time of trial group was 669 d, which was significantly longer than 410 d of control group, with statistical significance （P〈0.05）. Results of COX regression analysis showed that therapeutic efficacy of first-line chemotherapy influenced the survival of patients in different antihypertensive agent groups （P〈0.05）. CONCLU- SIONS： Compared with other antihypertensive drugs, ACEI/ARB agents significantly improve response rate of first-line chemother- apy in patients with advanced gastric cancer complicated with hypertension, si
出处
《中国药房》
CAS
北大核心
2017年第32期4517-4520,共4页
China Pharmacy
基金
浙江省药学会医院药学专项科研资助项目(No.2013ZYY06)
